Brought to you by 
Abgenix, AstraZeneca develop monoclonal antibodies for cancer
Oct 2003
Executive Summary
AstraZeneca and Abgenix (develops human therapeutic antibodies) entered an agreement for the discovery, development, and commercialization of fully human monoclonal antibodies to treat cancer.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R+D and Marketing-Licensing
- Includes Equity
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abgenix, AstraZeneca develop monoclonal antibodies for cancer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice